PMV Pharmaceuticals Posts Q1 GAAP EPS of -$0.34, Exceeding Expectations by $0.03, with $165.8 Million in Cash and Marketable Securities as of March 31, 2025.

PMV Pharmaceuticals reported Q1 GAAP EPS of -$0.34, beating estimates by $0.03. The company had cash, cash equivalents, and marketable securities of $165.8 million as of March 31, 2023, providing a cash runway to end of 2026.

PMV Pharmaceuticals, Inc. (PMVP) reported its first-quarter 2025 financial results, showcasing a quarterly adjusted earnings per share (EPS) of -$0.34, which exceeded market expectations by $0.03. The company's cash, cash equivalents, and marketable securities stood at $165.8 million as of March 31, 2025, providing a cash runway until the end of 2026 [1].

The company's net loss for the quarter ended March 31, 2025, was $17.5 million compared to $15.3 million for the same period in 2024. Operating expenses reached $21.564 million, with research and development (R&D) expenses totaling $17.4 million, an increase of $4.2 million from the same period last year. General and administrative (G&A) expenses decreased to $4.1 million from $5.0 million in the same quarter last year [2].

PMV Pharma's interim analysis from the Phase 2 PYNNACLE clinical trial is expected in the middle of 2025, including data for approximately 50 patients. The trial is evaluating rezatapopt (PC14586) as a monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors. The company's co-founder, Dr. Arnold Levine, established the field of p53 biology, and PMV Pharma continues to build on this foundation with its precision oncology focus [2].

The company's cash balance of $165.8 million as of March 31, 2025, provides a strong financial position, supporting ongoing clinical trials and product development. PMV Pharma's strategic focus on small molecule, tumor-agnostic therapies targeting p53 mutations positions it as a leader in precision oncology [2].

References:
[1] https://www.tradingview.com/news/reuters.com,2025-05-09:newsml_PLX29B2E8:0-brief-pmv-pharmaceuticals-q1-eps-usd-0-34/
[2] https://www.globenewswire.com/news-release/2025/05/09/3078214/0/en/PMV-Pharmaceuticals-Reports-First-Quarter-2025-Financial-Results-and-Corporate-Highlights.html